Demonstrating how easy it is to “miss” news that may be important to at least a few members of the prostate cancer community, we have just learned that gallium-68 dotatate ([68Ga]dotatate) PET scanning was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2016 — but not specifically for use in the detection of metastatic or micrometastatic prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer | Tagged: dotatate, gallium-68, NET, neuroendocrine, PSMA | 4 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 